A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Clinical trial NCT06528301 · RECRUITING

Trial details

NCT number: NCT06528301
Sponsor: Umoja Biopharma
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, B-Cell Lymphoma, Non-Hodgkin (NHL)Lymphoma, Large B-Cell, Diffuse (DLBCL)Chronic Lymphocytic Leukemia (CLL)

Start date: 2025-03-10
Primary completion: 2029-03-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.